Novo Nordisk

News

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

News

Noom Med app and accompanying GLP-1 implements

Noom expands its GLP-1 range with 'microdose' package

Noom is offering 'microdoses' of semaglutide at a knock-down price, claiming they can prevent side effects but remain effective for weight loss.

News

Lilly trumpets heart health data with Mounjaro

Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.

News

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.

News

Novo Nordisk files high-dose Wegovy in EU

Novo Nordisk has moved quickly to file for approval of a higher-dose version of obesity drug Wegovy as it fends off stiff competition from Eli Lilly.

R&D

pharmaphorum podcast Episode 188a - Novo Nordisk and Veeva

Maximising value by uniting the digital backbone: On a new N...

Novo Nordisk and Veeva have entered into a new partnership for clinical development.

Novo Nordisk weakens again on interim results readout

Noom expands its GLP-1 range with 'microdose' package

Lilly trumpets heart health data with Mounjaro

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Novo Nordisk files high-dose Wegovy in EU

Maximising value by uniting the digital backbone: On a new N...

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

Novo Nordisk

Editor's Picks